Organoid-based High-throughput Screening

Organoid-based High-throughput Screening is a powerful tool that bridges the gap between traditional cell culture and in vivo testing. By leveraging the physiological and genetic relevance of organoids, researchers can accelerate the drug discovery process, predict clinical outcomes more accurately, and advance personalized and precision medicine. Despite some challenges, advancements in automation, data analysis, and organoid technology continue to expand the capabilities and applications of this promising field. Creative Bioarray utilizes advanced organoid-based high-throughput screening (HTS) technology to enhance drug discovery, disease modeling, and personalized medicine research. By integrating cutting-edge organoid culture systems with automated HTS platforms, we provide robust, physiologically relevant, and high-efficiency screening solutions.

Figure 1. Organoid-based High-throughput Screening

Leveraging the CellTiter-Glo® 3D Cell Viability Assay developed by Promega, we evaluated the viability of organoid cells with precision and reliability. This assay quantifies viable cells in patient-derived organoid (PDO) cultures by detecting intracellular ATP levels, which are a key indicator of metabolically active cells. By measuring ATP content, the assay provides an accurate assessment of cell viability, enabling a comprehensive evaluation of cellular health and functionality within the organoid models.

Creative Bioarray's organoid-based HTS platform offers exceptional opportunities for accelerating drug discovery and advancing precision medicine. Whether you are screening large compound libraries, developing patient-specific therapies, or exploring disease mechanisms, our innovative solutions and expert team can help you efficiently and accurately achieve your research objectives.

Case Study

Figure 2. High-throughput drug screening in metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids. ^[1] A. Representative bright-field and HE-stained images of patient-derived organoids (PDOs). B. Timeline for the preparation of PDOs and the high-throughput drug screening process. Assay quality and robustness were evaluated using the signal window (SW) and Z factor across three independent experiments, each consisting of ten plates. C. Primary screening of 1,816 compounds in the high-throughput screening (HTS) assay. Blue spots indicate compounds derived from oncology, while red spots indicate compounds derived from non-oncology. Axitinib, crizotinib, and JQ-1 were identified.

Reference

1. Cao, Chuanzhen et al. "Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveal potential therapeutic agents." Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 24,7 (2022): 1333-1346. doi:10.1007/s12094-021-02774-8

Explore Other Options

• 3D Spheroid & Organoid Culture Reagents
• 3D Spheroid Platform for Drug Development
• Genetic Engineering in Organoids
• Organoid Platform for Drug Development
• Organ-on-a-Chip Platform for Drug Development

• Organoid Models
• Organoid-Immune Co-Culture Models

For research use only. Not for any other purpose.